DADC
PBYI icon

D.A. Davidson & Co’s Puma Biotechnology PBYI Stock Holding History

D.A. Davidson & Co’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100
Closed -$8K – 1726
2017
Q2 		$8K Sell
100
-150
-60% -$8.39K ﹤0.01% 2111
2017
Q1 		$9K Hold
250
– – ﹤0.01% 2061
2016
Q4 		$7K Buy
250
+28
+13% +$1.21K ﹤0.01% 2187
2016
Q3 		$14K Buy
222
+72
+48% +$3.64K ﹤0.01% 1961
2016
Q2 		$4K Hold
150
– – ﹤0.01% 2166
2016
Q1 		$4K Hold
150
– – ﹤0.01% 2084
2015
Q4 		$11K Hold
150
– – ﹤0.01% 1881
2015
Q3 		$11K Buy
150
+145
+2,900% +$13.7K ﹤0.01% 1844
2015
Q2 		$0 Buy
+5
New +$905 ﹤0.01% 2270

Other funds holding PBYI

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.A. Davidson & Co's PBYI Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Puma Biotechnology (PBYI) in Q3 2017, closing a stake of 100 shares — an estimated $8K sold.

D.A. Davidson & Co first reported a position in PBYI in Q2 2015 and held it in 9 quarters. The position peaked at $14K in Q3 2016. 171 funds tracked by Wall St. Rank hold PBYI as of Q3 2017.

  • D.A. Davidson & Co reported no remaining Puma Biotechnology position as of Q3 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 100 Puma Biotechnology shares in Q3 2017, an estimated $8K.
  • D.A. Davidson & Co first reported a position in Puma Biotechnology in Q2 2015 and held it in 9 quarters.
  • D.A. Davidson & Co's Puma Biotechnology position peaked at $14K in Q3 2016.
  • 171 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.